Knowledge based identification of essential signaling from genome-scale siRNA experiments

BackgroundA systems biology interpretation of genome-scale RNA interference (RNAi) experiments is complicated by scope, experimental variability and network signaling robustness. Over representation approaches (ORA), such as the Hypergeometric or z-score, are an established statistical framework used to associate RNA interference effectors to biologically annotated gene sets or pathways. These methods, however, do not directly take advantage of our growing understanding of the interactome. Furthermore, these methods can miss partial pathway activation and may be biased by protein complexes. Here we present a novel ORA, protein interaction permutation analysis (PIPA), that takes advantage of canonical pathways and established protein interactions to identify pathways enriched for protein interactions connecting RNAi hits.ResultsWe use PIPA to analyze genome-scale siRNA cell growth screens performed in HeLa and TOV cell lines. First we show that interacting gene pair siRNA hits are more reproducible than single gene hits. Using protein interactions, PIPA identifies enriched pathways not found using the standard Hypergeometric analysis including the FAK cytoskeletal remodeling pathway. Different branches of the FAK pathway are distinctly essential in HeLa versus TOV cell lines while other portions are uneffected by siRNA perturbations. Enriched hits belong to protein interactions associated with cell cycle regulation, anti-apoptosis, and signal transduction.ConclusionPIPA provides an analytical framework to interpret siRNA screen data by merging biologically annotated gene sets with the human interactome. As a result we identify pathways and signaling hypotheses that are statistically enriched to effect cell growth in human cell lines. This method provides a complementary approach to standard gene set enrichment that utilizes the additional knowledge of specific interactions within biological gene sets.

[1]  Adam A. Friedman,et al.  Genetic Screening for Signal Transduction in the Era of Network Biology , 2007, Cell.

[2]  I. Weinstein Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[3]  Xin Lu,et al.  Systems analysis of quantitative shRNA-library screens identifies regulators of cell adhesion , 2008 .

[4]  K Weber,et al.  Identification of essential genes in cultured mammalian cells using small interfering RNAs. , 2001, Journal of cell science.

[5]  Robert Gentleman,et al.  Assessing The Role Of Multi-protein Complexes In Determining Phenotype , 2008 .

[6]  H. Kitano,et al.  A comprehensive pathway map of epidermal growth factor receptor signaling , 2005, Molecular systems biology.

[7]  Peter S. Linsley,et al.  Small Interfering RNA Screens Reveal Enhanced Cisplatin Cytotoxicity in Tumor Cells Having both BRCA Network and TP53 Disruptions , 2006, Molecular and Cellular Biology.

[8]  Xiaoqi Liu,et al.  Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  E. Ruppin,et al.  Multiple knockout analysis of genetic robustness in the yeast metabolic network , 2006, Nature Genetics.

[10]  Carol V Robinson,et al.  Structural Characterization of the Human Eukaryotic Initiation Factor 3 Protein Complex by Mass Spectrometry*S , 2007, Molecular & Cellular Proteomics.

[11]  Ronald W. Davis,et al.  Functional profiling of the Saccharomyces cerevisiae genome , 2002, Nature.

[12]  Lucas Pelkmans,et al.  Lessons from genetics: interpreting complex phenotypes in RNAi screens. , 2008, Current opinion in cell biology.

[13]  Arun K. Ramani,et al.  How complete are current yeast and human protein-interaction networks? , 2006, Genome Biology.

[14]  Norbert Perrimon,et al.  High-throughput approaches to dissecting MAPK signaling pathways. , 2006, Methods.

[15]  S. Haney Increasing the robustness and validity of RNAi screens. , 2007, Pharmacogenomics.

[16]  A. Ashworth,et al.  Utilizing RNA interference to enhance cancer drug discovery , 2007, Nature Reviews Drug Discovery.

[17]  N. Perrimon,et al.  Genome-Wide RNAi Analysis of Growth and Viability in Drosophila Cells , 2004, Science.

[18]  A. Hyman,et al.  Genome-scale RNAi profiling of cell division in human tissue culture cells , 2007, Nature Cell Biology.

[19]  U. Knaus,et al.  P21-activated kinase is required for mitotic progression and regulates Plk1 , 2008, Oncogene.

[20]  Z. Hua,et al.  FAK expression regulation and therapeutic potential. , 2008, Advances in cancer research.

[21]  Wolfgang Huber,et al.  Analysis of cell-based RNAi screens , 2006, Genome Biology.

[22]  M. Orešič,et al.  Pathways to the analysis of microarray data. , 2005, Trends in biotechnology.

[23]  Gene Ontology Consortium The Gene Ontology (GO) database and informatics resource , 2003 .

[24]  P. Khatri,et al.  A systems biology approach for pathway level analysis. , 2007, Genome research.

[25]  Scott E. Martin,et al.  Applications of RNA interference in mammalian systems. , 2007, Annual review of genomics and human genetics.

[26]  J. Castle,et al.  expression data: the tissue distribution of human pathways , 2006 .

[27]  Peter S. Linsley,et al.  Small Interfering RNA Screens Reveal Enhanced Cisplatin Cytotoxicity in Tumor Cells Having both BRCA Network and TP 53 Disruptions ‡ , 2006 .

[28]  S. Horvath,et al.  Statistical Applications in Genetics and Molecular Biology , 2011 .

[29]  M. Oti,et al.  The modular nature of genetic diseases , 2006, Clinical genetics.

[30]  Z. Hua,et al.  Chapter 3 FAK Expression , 2008 .

[31]  Robert Gentleman,et al.  A graph-theoretic approach to testing associations between disparate sources of functional genomics data , 2004, Bioinform..